权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Development of novel "patient-tailored DDS"by plasma technique

利用等离子体技术开发新型“患者定制DDS”

基本信息

批准号：
14370730
负责人：
KUZUYA Masayuki
金额：
$ 8.26万
依托单位：
Gifu Pharmaceutical University
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (B)
财政年份：
2002
资助国家：
日本
起止时间：
2002 至 2004
项目状态：
已结题

来源：
https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-14370730/
关键词：
plasma treatment patient-tailored DDS time-controlled DDS intragastric floating DDS drv orocess crosslinking reaction controlled release oral drug delivery ラグタイム熱効果ガラス転移点

项目摘要

Although oral delivery is convenient to administration and acceptable for patients, the therapeutic effects often depend on the each patient's gastrointenstinal (GI) environment. Therefore, the "Patient-Tailored Drug Delivery System (DDS)" should be developed and administered based on the diagnosis of each patient's GI environment. We have studied plasma-assisted preparation of time-controlled DDS and intragastric floating DDS (FDDS) leading to the "Patient-Tailored DDS" targeting the GI tract. Double-compressed tablets composed of drug tablet as a core material and polymer powder, which was used as pharmaceutical aids, as a wall material was prepared to fabricate time-controlled DDS and inttragastric FDDS.Since plasma-crosslinkable acrylic monomers are one of the component polymers in Eudragits L100-55, argon plasma-irradiation would lead to the suppression of Eudragit L100-55 solubility even in a dissoluble pH-value solution due to the occurrence of the surface cross-link reactions. … More When Eudragit L100-55 is used as a wall material of the double-compressed tablet, the initial drug release could be completely sustained for a certain period of time. The lag-time could be controlled by plasma operational conditions.We have obtained the intragastric FDDS by plasma-irradiation when the double-compressed tablet was prepared using the outer layer to trap evolved carbon dioxide. The double-compressed tablet was prepared using methyl vinyl ether-maleic anhydride copolymer (VEMA), and a mixture of VEMA and hydroxypropyl methylcellulose phthalate as an outer layer. It was found that the tablet plasma-irradiated remains buoyant in the simulated gastric fluids for a prolonged period of time, and the drug release is considerably suppressed. The drug release can be controlled at a desired rate from the tablets by selecting the plasma operational tunings.The present results have clearly shown that one can prepare a variety of desired DDS devices, if one selects the tailored-polymers for wall materials of double-compressed tablets as well as plasma operational conditions. Less

虽然口服给药方便且患者可接受，但治疗效果往往取决于每个患者的胃肠道（GI）环境。因此，“患者定制给药系统”（DDS）应根据每个患者胃肠道环境的诊断来开发和给药。我们研究了血浆辅助制备时间控制DDS和胃内浮动DDS (FDDS)，从而实现针对胃肠道的“患者定制DDS”。制备了以药物片剂为核心材料，高分子粉末为壁材的双压缩片剂，用于制备定时控制DDS和灌胃FDDS。由于等离子体交联丙烯酸单体是Eudragit L100-55的组份聚合物之一，氩等离子体辐照会导致Eudragit L100-55在可溶解的ph值溶液中由于表面交联反应的发生而抑制其溶解度。当Eudragit L100-55作为双压缩片剂的壁材时，初始药物释放可以在一定时间内完全持续。滞后时间可以通过等离子体操作条件来控制。在制备双压缩片剂的过程中，利用外层截留释放出的二氧化碳，采用等离子体辐照法获得了FDDS。以甲基乙烯醚-马来酸酐共聚物（VEMA）为原料，VEMA与邻苯二甲酸羟丙基甲基纤维素盐的混合物为外层制备双压缩片剂。结果表明，经等离子体辐照后的片剂在模拟胃液中长时间保持浮力，药物释放明显受到抑制。通过选择等离子体操作调谐，可以将药物释放控制在所需的速率。目前的结果清楚地表明，如果选择适合双压缩片剂壁材和等离子体操作条件的聚合物，可以制备各种所需的DDS器件。少